BAM
ZVRA icon

Belpointe Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Belpointe Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-286
Closed -$1.57K – 3463
2023
Q1 		$1.57K Hold
286
– – ﹤0.01% 3377
2022
Q4 		$1.31K Buy
+286
New +$1.45K ﹤0.01% 3380

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Belpointe Asset Management's ZVRA Position: Q2 2023 in Review

Belpointe Asset Management sold out of Zevra Therapeutics (ZVRA) in Q2 2023, closing a stake of 286 shares — an estimated $1.57K sold.

Belpointe Asset Management first reported a position in ZVRA in Q4 2022 and held it in 2 quarters. The position peaked at $1.57K in Q1 2023. 71 funds tracked by Wall St. Rank hold ZVRA as of Q2 2023.

  • Belpointe Asset Management reported no remaining Zevra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 286 Zevra Therapeutics shares in Q2 2023, an estimated $1.57K.
  • Belpointe Asset Management first reported a position in Zevra Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Zevra Therapeutics position peaked at $1.57K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.